Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC
{{output}}
Introduction: Concurrent chemoradiotherapy (cCRT) is the standard of care for unresectable stage III NSCLC, but whether EGFR mutation is a prognostic factor remains unclear. This study evaluated the efficacy and safety of cCRT in... ...
